Indevus in deal with Teva for pagoclone in stuttering
This article was originally published in Scrip
Indevus Pharmaceuticalshas signed a development and licensing agreement with Teva Pharmaceuticals Industriesfor the exclusive worldwide rights to the novel product, pagoclone, in development as a treatment for persistent stuttering. Under the deal, Teva will reimburse Phase IIb expenses incurred by Indevus, the company said. A previous eight-week Phase II trial showed that pagoclone produced a statistically significant benefit in multiple primary and secondary stuttering endpoints compared with placebo; pagoclone is a novel member of the cyclopyrrolone class of compounds and acts as a gamma-amino butyric acid (GABA) selective receptor modulator. After completion of a successful Phase IIb trial, the agreement provides for Indevus to participate on a 50/50 basis with Teva in the US, sharing development and marketing costs and splitting future profits in addition to receiving milestone payments.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.